SARS-CoV-2 Envelope antibody (N-Term)

Catalog No. ABIN1031551

This Rabbit Polyclonal antibody specifically detects SARS-CoV-2 Envelope in ELISA, IF and IHC. It exhibits reactivity toward SARS Coronavirus-2 (SARS-CoV-2) and SARS Coronavirus (SARS-CoV) and has been mentioned in 9+ publications.

Quick Overview for SARS-CoV-2 Envelope antibody (N-Term) (ABIN1031551)

Target: SARS-CoV-2 Envelope (SARS-CoV-2 E)

Reactivity: SARS Coronavirus-2 (SARS-CoV-2), SARS Coronavirus (SARS-CoV)

Host: Rabbit

Clonality: Polyclonal

Conjugate: This SARS-CoV-2 Envelope antibody is un-conjugated

Application: ELISA, Immunofluorescence (IF), Immunohistochemistry (IHC)

Product Details anti-SARS-CoV-2 Envelope Antibody

Binding Specificity: N-Term

Predicted Reactivity: Predicted reactivity based on immunogen sequence: SARS-CoV Envelope proteins: (100%)

Purification: Affinity chromatography purified via peptide column

Immunogen: Anti-SARS-CoV-2 (COVID-19, 2019-nCoV) Envelope antibody was raised against a peptide corresponding to 10 amino acids near the amino terminus of SARS-CoV-2 (COVID-19, 2019-nCoV) Envelope protein.
The immunogen is located within the first 50 amino acids of SARS-CoV-2 (COVID-19, 2019-nCoV) Envelope.

Isotype: IgG

Application Details

Application Notes: SARS-CoV-2 (COVID-19, 2019-nCoV) Envelope antibody can be used for the detection of SARS-CoV-2 (COVID-19, 2019-nCoV) Envelope protein in ELISA. It will detect 20 ng of free peptide at 1 μg/mL.

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 1 mg/mL

Buffer: The antibody is supplied in PBS containing 0.02% sodium azide.

Preservative: Sodium azide

Precaution of Use: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handling Advice: As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

Storage: 4 °C/-20 °C

Storage Comment: The antibody can be stored at 4 ˚ C for three months and -20 ˚ C, stable for up to one year.

Expiry Date: 12 months

References for anti-SARS-CoV-2 Envelope antibody (ABIN1031551)

Magro, Mulvey, Laurence, Sanders, Crowson, Grossman, Harp, Nuovo: "The differing pathophysiologies that underlie COVID-19-associated perniosis and thrombotic retiform purpura: a case series." in: The British journal of dermatology, Vol. 184, Issue 1, pp. 141-150, (2021) (PubMed).

Vojdani, Vojdani, Kharrazian: "Reaction of Human Monoclonal Antibodies to SARS-CoV-2 Proteins With Tissue Antigens: Implications for Autoimmune Diseases." in: Frontiers in immunology, Vol. 11, pp. 617089, (2021) (PubMed).

Magro, Mulvey, Berlin, Nuovo, Salvatore, Harp, Baxter-Stoltzfus, Laurence: "Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases." in: Translational research : the journal of laboratory and clinical medicine, Vol. 220, pp. 1-13, (2020) (PubMed).

Mulvey, Magro, Ma, Nuovo, Baergen: "Analysis of complement deposition and viral RNA in placentas of COVID-19 patients." in: Annals of diagnostic pathology, Vol. 46, pp. 151530, (2020) (PubMed).

Nuovo, Tili, Suster, Matys, Hupp, Magro et al.: "Strong homology between SARS-CoV-2 envelope protein and a Mycobacterium sp. antigen allows rapid diagnosis of Mycobacterial infections and may provide specific anti-SARS-CoV-2 immunity via the BCG ..." in: Annals of diagnostic pathology, Vol. 48, pp. 151600, (2020) (PubMed).

Yurkovetskiy, Wang, Pascal, Tomkins-Tinch, Nyalile, Wang, Baum, Diehl, Dauphin, Carbone, Veinotte, Egri, Schaffner, Lemieux, Munro, Rafique, Barve, Sabeti, Kyratsous, Dudkina, Shen, Luban: "Structural and Functional Analysis of the D614G SARS-CoV-2 Spike Protein Variant." in: Cell, Vol. 183, Issue 3, pp. 739-751.e8, (2020) (PubMed).

Schöler, Le-Trilling, Eilbrecht, Mennerich, Anastasiou, Krawczyk, Herrmann, Dittmer, Trilling: "A Novel In-Cell ELISA Assay Allows Rapid and Automated Quantification of SARS-CoV-2 to Analyze Neutralizing Antibodies and Antiviral Compounds." in: Frontiers in immunology, Vol. 11, pp. 573526, (2020) (PubMed).

Nuovo, Magro, Mikhail: "Cytologic and molecular correlates of SARS-CoV-2 infection of the nasopharynx." in: Annals of diagnostic pathology, Vol. 48, pp. 151565, (2020) (PubMed).

Ventura, Cennamo, Minopoli, Campanile, Censi, Terracciano, Portella, Velotta: "Colorimetric Test for Fast Detection of SARS-CoV-2 in Nasal and Throat Swabs." in: ACS sensors, Vol. 5, Issue 10, pp. 3043-3048, (2020) (PubMed).

Target Details for SARS-CoV-2 Envelope

Target: SARS-CoV-2 Envelope (SARS-CoV-2 E)

Alternative Name: SARS-CoV-2 Envelope Protein

Target Type: Viral Protein

Background: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus. The disease is the cause of the 2019–20 coronavirus outbreak. The structure of 2019-nCoV consists of the following: a spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Envelope protein is a small polypeptide that contains at least one α-helical transmembrane domain. It involves in several aspects of the virus's life cycle, such as assembly, budding, envelope formation, and pathogenesis. E protein has membrane permeabilizing activity, which provides a possible rationale to inhibit in vitro ion channel activity of some synthetic coronavirus E proteins, and also viral replication.

Gene ID: 43740570

NCBI Accession: QHD43418